Association of JAK/STAT signaling pathway with portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension

Huan WANG; Xiaoxu SHEN; Liangqi CHEN; Tianlan GONG

doi:10.3969/j.issn.1001-5256.2022.10.012

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2260-2264

PDF( 1970 KB)

Association of JAK/STAT signaling pathway with portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.10.012

Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guizhou 550002, China

Research funding:

Guiyang Science and Technology Planning Project ([2019]9-5-11)

More Information

Corresponding author: SHEN Xiaoxu, 512916746@qq.com(ORCID: 0000-0002-0055-6987)
Received Date: 2022-03-04
Accepted Date: 2022-04-29
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the role of the Janus tyrosine kinase (JAK)- signal transducer and activators of transcription (STAT) signaling pathway in thrombosis formation after splenectomy in cirrhotic patients with portal hypertension. Methods A total of 198 liver cirrhosis patients with portal hypertension who underwent splenectomy and devascularization were recruited from March 2018 to April 2020 and then divided into thrombosis (n=41) and non-thrombosis groups (n=157) according to whether portal vein thrombosis occurred 3 months after surgery. mRNA levels of JAK2 and STAT3 in peripheral blood mononuclear cells (PBMCs) were assessed. Comparison of continuous data between groups was performed using t test, while comparison of categorial data between group was performed using chi square test. Clinicopathological data from patients were collected and analyzed for the potential risk factors of portal vein thrombosis by using univariate and multivariate Logistic regression analyses. The prediction values of JAK2 and STAT3 mRNA for portal vein thrombosis were evaluated by area under the receiver operating curve (AUC). Results The diameter of portal vein, the diameter of portal vein, the velocity difference of portal vein and the volume of spleen in the thrombus group were significantly higher than those in the non-thrombus group (t=4.718, 3.945, 8.671, and 2.006 respectively; P < 0.05).The relative mRNA levels of JAK2 and STAT3 in PBMCs of the two groups were significantly increased after surgery (t=12.933, 15.442, 14.386, 10.896; P < 0.05), and their levels were also much higher in the thrombosis group than in the non-thrombosis group of patients (P < 0.05). Multivariate Logistic regression analytic data showed that the portal vein diameter, the velocity difference of portal vein and mRNA level of JAK2 and STAT3 were all predictors for thrombosis in these patients (P < 0.05). The AUC of JAK2 and STAT3 mRNAs was 0.850 and 0.787, respectively in diagnosis of thrombosis in these patients. Conclusion The JAK / STAT signaling was activated in the process of thrombosis after splenectomy in cirrhotic patients with portal hypertension, which may be one of the important mechanisms of postoperative portal vein thrombosis, and may become a potential target for the prevention and treatment of postoperative portal vein thrombosis.
- Liver Cirrhosis,
- Hypertension,
- Portal,
- Splenectomy

FullText(HTML)

References(18)

References

[1]	SIMONETTO DA, LIU M, KAMATH PS. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4): 714-726. DOI: 10.1016/j.mayocp.2018.12.020.
[2]	JIANG GQ, BAI DS, JIN SJ, et al. Modified vagus nerve-preserving versus conventional laparoscopic splenectomy and azygoportal disconnection for cirrhotic portal hypertension: a prospective randomized controlled trial[J]. Chin J Dig Surg, 2020, 19(12): 1280-1285. DOI: 10.3760/cma.j.cn115610-20201126-00741. 蒋国庆, 柏斗胜, 金圣杰, 等. 改良保留迷走神经与传统腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的前瞻性随机对照研究[J]. 中华消化外科杂志, 2020, 19(12): 1280-1285. DOI: 10.3760/cma.j.cn115610-20201126-00741.
[3]	HAN D, PENG JW, XIE HJ. Prevention of portal vein thrombosis in patients with cirrhotic portal hypertension aftersplenectomy and devascularization[J]. J Prac Hepatol, 2020, 23(3): 409-412. DOI: 10.3969/j.issn.1672-5069.2020.03.027. 韩东, 彭经纬, 谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究[J]. 实用肝脏病杂志, 2020, 23(3): 409-412. DOI: 10.3969/j.issn.1672-5069.2020.03.027.
[4]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[5]	SONG ZM, DAI CL. Progress in diagnosis and treatment of portal vein thrombosis after splenectomy for cirrhosis and portal hypertension[J]. Chin J Curr Adv Gen Surg, 2019, 22(12): 958-962. DOI: 10.3969/j.issn.1009-9905.2019.12.009. 宋子敏, 戴朝六. 肝硬化门脉高压症脾切除术后门静脉系统血栓形成的诊治进展[J]. 中国现代普通外科进展, 2019, 22(12): 958-962. DOI: 10.3969/j.issn.1009-9905.2019.12.009.
[6]	QI R, JIN X, SHI H, et al. Effect of laparoscopic splenectomy on portal vein thrombosis and serum YKL-40 in patients with cirrhotic portal hypertension[J]. Ann Hepatol, 2019, 18(6): 898-901. DOI: 10.1016/j.aohep.2019.06.009.
[7]	LI DY. Comparison of different intra-splenectomy splenic pedicle vascular treatments for postoperative portal vein thrombosis in cirrhotic portal hypertension[J]. Guangxi Med J, 2019, 41(8): 985-988. DOI: 10.11675/j.issn.0253-4304.2019.08.14. 李丹阳. 肝硬化门静脉高压症脾切除术中不同脾蒂血管处理方法对术后门静脉血栓形成的对比研究[J]. 广西医学, 2019, 41(8): 985-988. DOI: 10.11675/j.issn.0253-4304.2019.08.14.
[8]	ZHANG XY, LI C, PENG W, et al. Platelet count-spleen volume ratio prediction of both moderate and severe portal hypertention in patients with cirrhosis by platelet count-spleen volume ratio[J]. J Abdominal Surg, 2016, 29(3): 187-192. DOI: 10.3969/j.issn.1003-5591.2016.03.009. 张晓赟, 李川, 彭伟, 等. 血小板/脾脏体积比预测肝硬化门静脉高压症的严重程度[J]. 腹部外科, 2016, 29(3): 187-192. DOI: 10.3969/j.issn.1003-5591.2016.03.009.
[9]	XIONG ZJ, FAN HS, ZHU XN, et al. Application of FibroTouch combined with AST to platelet ratio index in diagnosis of portal hypertension in patients with hepatic cirrhosis[J/CD]. Chin J Hepat Surg(Electronic Edition), 2019, 8(4): 362-365. DOI: 10.3877/cma.j.issn.2095-3232.2019.04.019. 熊志娇, 范红顺, 朱先女, 等. FibroTouch联合AST-血小板比值指数在肝硬化门静脉高压症诊断中的应用[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(4): 362-365. DOI: 10.3877/cma.j.issn.2095-3232.2019.04.019.
[10]	SONG LJ, YUAN Y, WANG W. Clinical value of quantitative magnetic resonance imaging in the diagnosis of portal hypertension in patients with primary biliary cirrhosis[J]. J Prac Hepatol, 2020, 23(4): 568-571. DOI: 10.3969/j.issn.1672-5069.2020.04.029. 宋丽俊, 袁雁, 王伟. 定量磁共振成像诊断原发性胆汁性肝硬化患者门静脉高压症价值分析[J]. 实用肝脏病杂志, 2020, 23(4): 568-571. DOI: 10.3969/j.issn.1672-5069.2020.04.029.
[11]	GIOIA S, NARDELLI S, PASQUALE C, et al. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis[J]. Dig Liver Dis, 2018, 50(8): 839-844. DOI: 10.1016/j.dld.2018.01.132.
[12]	LYU SC, GU WQ. Research progress on prevention and treatment of portal vein thrombosis after splenectomy for patients with hepatic cirrhosis[J]. Chin J Hepatobiliary Surg, 2015, 21(1): 59-63. DOI: 10.3760/cma.j.issn.1007-8118.2015.01.019. 吕少诚, 顾万清. 肝硬化患者脾切除术后门静脉血栓的防治研究进展[J]. 中华肝胆外科杂志, 2015, 21(1): 59-63. DOI: 10.3760/cma.j.issn.1007-8118.2015.01.019.
[13]	YANG S, HE C, FAN X, et al. Early prophylactic anticoagulation via transjugular intrahepatic route for portal vein thrombosis after splenectomy in cirrhotic portal hypertension[J]. J Vasc Interv Radiol, 2015, 26(7): 1009-1017. DOI: 10.1016/j.jvir.2015.03.008.
[14]	FENG Q, XU C, SUN MH. miR-141 inhibits thrombosis in vascular pathways through the TLR4 signaling pathway[J]. Med J West China, 2021, 33(2): 186-190. DOI: 10.3969/j.issn.1672-3511.2021.02.006. 冯琦, 徐超, 孙明慧. miRNA-141通过调节TLR4信号通路抑制大鼠血栓形成[J]. 西部医学, 2021, 33(2): 186-190. DOI: 10.3969/j.issn.1672-3511.2021.02.006.
[15]	GU YN, XIE CY. Advancing investigate of deep vein thrombosis for inflammation and signa-ling pathway[J]. Chin J Immunol, 2020, 36(1): 113-118. DOI: 10.3969/j.issn.1000-484X.2020.01.022. 顾燕妮, 谢春毅. 深静脉血栓形成炎症信号通路研究进展[J]. 中国免疫学杂志, 2020, 36(1): 113-118. DOI: 10.3969/j.issn.1000-484X.2020.01.022.
[16]	MALEMUD CJ. The role of the JAK/STAT signal pathway in rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis, 2018, 10(5-6): 117-127. DOI: 10.1177/1759720X18776224.
[17]	BANERJEE S, BIEHL A, GADINA M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects[J]. Drugs, 2017, 77(5): 521-546. DOI: 10.1007/s40265-017-0701-9.
[18]	LI Y, LI KH, WEN SH, et al. Role of JAK/STAT in intestinal injury induced by intestinal ischemia/reperfusion in rats[J]. Chin J Pathophysioly, 2011, 27(12): 2338-2344. DOI: 10.3969/j.issn.1000-4718.2011.12.019. 李毅, 李坤河, 温仕宏, 等. JAK/STAT通路在大鼠肠缺血再灌注所致肠损伤中的作用[J]. 中国病理生理杂志, 2011, 27(12): 2338-2344. DOI: 10.3969/j.issn.1000-4718.2011.12.019.

Relative Articles

[1]	Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
[2]	Wanshu LIU, Lijun SHEN, Qinghui ZHAI, Shaojie XIN, Shaoli YOU. Risk factors for acute variceal bleeding in acute-on-chronic liver failure and its influence on prognosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2532-2536. doi: 10.3969/j.issn.1001-5256.2022.11.018
[3]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[4]	Jincheng WANG, Peihe YU, Song SU, Bo LI. Clinical effect of endoscopic nasobiliary drainage versus endoscopic biliary stenting in preoperative biliary drainage for low-level malignant obstructive jaundice: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(4): 863-867. doi: 10.3969/j.issn.1001-5256.2021.04.027
[5]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[6]	Yang DongXiao, Zhang Yong, Wang XueFeng, Li Jiang. Application of ultrasound-guided real-time percutaneous transhepatic-cholangial or transhepatic-cholecyst drainage in treatment of acute obstructive cholangitis in primary hospitals[J]. Journal of Clinical Hepatology, 2020, 36(4): 847-849. doi: 10.3969/j.issn.1001-5256.2020.04.027
[7]	Peng FengHui, Liu Kai, Yang Yang, Liu YaHui, Ji Bo. Biliary stent implantation for malignant obstructive jaundice through the percutaneous transhepatic biliary drainage pathway: A report of 2 cases[J]. Journal of Clinical Hepatology, 2019, 35(7): 1601-1603. doi: 10.3969/j.issn.1001-5256.2019.07.038
[8]	Huang Jian, Jiang BeiGe, Yang Yuan, Gu FangMing, Yuan ShengXian, Pan ZeYa. Influencing factors for the prognosis of patients with early-stage intrahepatic cholangiocarcinoma after radical resection[J]. Journal of Clinical Hepatology, 2018, 34(10): 2157-2163. doi: 10.3969/j.issn.1001-5256.2018.10.019
[9]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[10]	Xing ZhiXiang, Shen ShiQiang, Qin Feng, Yang Qiang, Ye Zi. Effect of postoperative adjuvant transarterial chemoembolization on postoperative survival of patients with liver cancer and related influencing factors for prognosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2331-2336. doi: 10.3969/j.issn.1001-5256.2017.12.015
[11]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[12]	Shi XinXing, Zhang YanQiong, Zhu Peng, Yan GuoHua, Zhang ZhangJiang, Wang YuMing. Prognostic risk factors in patients with hepatitis B virus- related acute- on- chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(4): 700-705. doi: 10.3969/j.issn.1001-5256.2016.04.018
[13]	Cui YanPing, Li QingFang, Li QingYan, Liu ChunHua, Wang WeiHong, Yuan JianGuo, Wang SiKui. Logistic regression analysis of prognostic risk factors for hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2016, 32(1): 135-138. doi: 10.3969/j.issn.1001-5256.2016.01.026
[14]	Zhang ZhiQuan. Analysis of prognostic factors for patients treated by radical resection of liver metastases from colorectal cancer[J]. Journal of Clinical Hepatology, 2015, 31(9): 1455-1457. doi: 10.3969/j.issn.1001-5256.2015.09.022
[15]	Chen QiuLian, Wu ShanShan, Liu ChaoHui. Clinical application of preoperative biliary drainage in malignant obstructive jaundice with acute cholangitis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1652-1655. doi: 10.3969/j.issn.1001-5256.2015.10.023
[16]	Wang WenJun, Yu CongHui. Improvement in liver function in patients with malignant obstructive jaundice after endoscopic biliary metallic stent drainage[J]. Journal of Clinical Hepatology, 2015, 31(8): 1295-1298. doi: 10.3969/j.issn.1001-5256.2015.08.027
[17]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[18]	Lu: RiYing, Li ShiXiong, Wu JiZhou, Zhu YuJia, Fu ShaoPing. Development of a prognostic factors model for severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(10): 789-792.
[19]	Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155.
[20]	Ding HuiGuo, Gao GuiJu, Chen Tao, Jin Rui. Prognosis of Severe Types of Virous Hepatitis: Study on Mutiple Risk Factors.[J]. Journal of Clinical Hepatology, 2002, 18(5): 297-299.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	陈佳良，王宪波. 中医药治疗原发性胆汁性胆管炎研究进展. 西南医科大学学报. 2025(01): 21-26 .
2.	黄江梅，高云堃，张桂林，朱英嵽，黄华，赵公芳. 幽门螺杆菌感染与原发性胆汁性胆管炎的关系研究. 中国现代药物应用. 2025(02): 30-33 .
3.	张梓珊，张耀武，李梦桃. 治疗原发性胆汁性胆管炎的新型药物综述. 中西医结合肝病杂志. 2024(08): 749-754 .
4.	王宪波. 原发性胆汁性胆管炎中西医结合诊疗专家共识. 临床肝胆病杂志. 2024(09): 1757-1766 . 本站查看
5.	周莉涵，郭晟，张凡，李逸雪，徐子皓，程良斌. 基于“主客交”理论辨治原发性胆汁性胆管炎. 湖北中医药大学学报. 2023(05): 54-58 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (420) PDF downloads(30)

Association of JAK/STAT signaling pathway with portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.10.012